<!DOCTYPE html>
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="robots" content="noindex">
<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
<link href="css-reset.css" rel="stylesheet" type="text/css">
<link href="style.css" rel="stylesheet" type="text/css">
<link rel="shortcut icon" href="favicon.ico" type="image/x-icon">
<link rel="icon" href="favicon.ico" type="image/x-icon">
<title>IONSYS™ (fentanyl iontophoretic transdermal system)</title> 
</head>

<body>
<div class="phonegapBlack">
	<div>
		<div class="introLogo">
		</div>
		<p>
			IONSYS on tarkoitettu leikkauksen jälkeisen äkillisen, kohtalaisen tai vakavan kivun hallintaan aikuisilla potilailla.
			<br><br>
			IONSYS on tarkoitettu vain sairaalakäyttöön. Hoidon saa aloittaa ja sen tulee pysyä sellaisen lääkärin valvonnassa, jolla on kokemusta opioidihoidon suorittamisesta.
			<br><br>
			Tap to continue.
		</p>
	</div>
</div>
<div class="languageBar">
	<div class="languageList hiddenList">
		<ul>
			<a href="index_AT.html"><li class="language "><span>AT</span></li></a>
			<a href="index_DA.html"><li class="language "><span>DA</span></li></a>
			<a href="index_DE.html"><li class="language "><span>DE</span></li></a>
			<a href="index.html"><li class="language "><span>GB</span></li></a>
			<a href="index_FR.html"><li class="language "><span>FR</span></li></a>
			<a href="index_NL.html"><li class="language "><span>NL</span></li></a>
			<a href="index_NO.html"><li class="language "><span>NO</span></li></a>
			<a href="index_SE.html"><li class="language "><span>SE</span></li></a>
		</ul>
	</div>	
	<div class="languageSelector"></div>
</div>

<header class="pageHeader frontHeader">
	<div id="headerLogoCircle hidden">
	</div>
</header>

<header class="pageHeader frontHeader powerButtonContainer">
	<button id="powerButton">
		<i class="flaticon-standby"></i>
	</button>
	<button id="powerButtonOff">
		<i class="flaticon-standby"></i>
	</button>
</header>	
<section class="splash">
	<div class="splashLimiter">
		<header class="ionsysLogo">
		</header>
		<div class="backgroundAssembly"></div>
		<div class="container packageAssembly">
			<div class="bottomAssy">
				<div class="bottomAssySnapPoint"></div>
			</div>
			<div class="topAssy" draggable="true">
			</div>
		</div>
		<div class="container workingAssembly hidden">
			<div class="device" id="ionsysSplash">
				<div class="led ledGreen hidden">
				</div>
				<div class="led ledRed hidden">
				</div>
				<div class="doseButton">
				</div>
				<div class="seven-segment">
					<div class="digit tens">
						  <div class="a"></div>
						  <div class="b"></div>
						  <div class="c"></div>
						  <div class="d"></div>
						  <div class="e"></div>
						  <div class="f"></div>
						  <div class="g"></div>
					</div>
					<div class="digit ones">
						  <div class="a"></div>
						  <div class="b"></div>
						  <div class="c"></div>
						  <div class="d"></div>
						  <div class="e"></div>
						  <div class="f"></div>
						  <div class="g"></div>
					</div>
				</div>
			</div>
			<div id="medcoLogo" class="hidden">
				<img src="img-medcologo-long-black-clr.png">
			</div>
		</div>
		<div class="container context invisible">
			<div class="contextOverflow">
				<div class="contextContent">
					<header>
						<h2 id="deviceStatus">
							<p class="statusDefault enable"></p>
							<p class="statusReady">Valmiustila</p>
							<p class="statusDose1">Annostelu</p>
							<p class="statusDose2">Annostelu</p>
							<p class="statusPsc1">Heikko ihokontakti</p>
							<p class="statusPsc2">Heikko ihokontakti</p>
							<p class="statusEou">Käytön lopettaminen</p>
							<p class="statusEol">Valmisteessa vika</p>
							<p class="statusPoweron">Virran kytkeminen päälle</p>
							<p class="statusPoweroff"><!-- Powering Off --></p>
							<p class="statusPoweredoff"><!-- Powered Off --></p>
							<p class="statusCustom">custom</p>
						</h2>
					</header>
					<article class="caption">
						<h4 id="modeCaption" class="hidden">
							<p class="statusDefault enable"></p>
							<p class="statusReady">Valmis annostelun aloittamiseen</p>
							<p class="statusDose1">Annostelua suoritetaan...</p>
							<p class="statusDose2">Annostelua suoritetaan...</p>
							<p class="statusPsc1">Annosta EI anneta</p>
							<p class="statusPsc2">Annosta EI anneta</p>
							<p class="statusEou">80 annosta tai 24 tuntia</p>
							<p class="statusEol">HÄLYTYStila</p>
							<p class="statusPoweron"><!-- Powering On --></p>
							<p class="statusPoweroff"><!-- Powering Off --></p>
							<p class="statusPoweredoff"><!-- Powered Off --></p>
							<p class="statusCustom">custom</p>
						</h4>
						<div id="modeDescription">
							<p class="statusDefault enable"></p>
							<p class="statusReady">
								Järjestelmässä on virta päällä, ja se on valmis annostelun aloittamiseen. Annos voidaan antaa painamalla laitteen yläosan annospainiketta kaksi kertaa niin, että painamiskertojen välillä on enintään 3 sekuntia. Fentanyyliä ei anneta laitteen tässä tilassa ennen kuin annoksen antaminen on aloitettu.
								<span class="mockButton mbEOU">
									Jos laite saavuttaa 24 tunnin tai 80 annoksen rajan, se siirtyy käytön lopettamisen tilaan.
								</span>
								<span class="mockButton mbEOL">
									Jos laitteen itsetestaus epäonnistuu tai akun varaus on vähäinen, laite HÄLYTTÄÄ ja siirtyy käytön lopettamisen tilaan.
								</span>
							</p>
							<p class="statusDose1">
								Fentanyyliannoksen antaminen. Annosteluvaihe kestää 10 minuuttia, jonka aikana potilas saa 40 mikrogrammaa lääkettä. Tämän vaiheen aikana annospainike on pois käytöstä, LED-valo vilkkuu vihreänä ja näyttö osoittaa laitteen olevan annostelutilassa liikkuvan LCD-animaation avulla, joka näkyy näytöllä vuorotellen annettavan annoksen näytön kanssa.
								<span class="mockButton mbPSC">
									Jos laite tunnistaa, että ihokontakti on heikko, se lopettaa annostelun, siirtyy lepotilaan ja palaa sitten valmiustilaan.
								</span>
								<span class="mockButton mbEOU">
									Jos laite saavuttaa 24 tunnin tai 80 annoksen rajan, se siirtyy käytön lopettamisen tilaan.
								</span>
								<span class="mockButton mbEOL">
									Jos laite tunnistaa, että ihossa on ongelmia (esim. avohaava), se HÄLYTTÄÄ ja siirtyy käytön lopettamisen tilaan.
								<span>
							</p>
							<p class="statusPsc1">
								Kun annostelu aloitetaan, MUTTA järjestelmä ei tunnista tarvittavaa kontaktia potilaan ihoon 4 minuutin jälkeen, laite lopettaa annostelun, siirtyy lepotilaan ja ilmoittaa asiasta potilaalle. Tämä tapahtuu kuuluvalla piippausäänellä, jonka aikana LED-valo vilkkuu punaisena.
								<span>
									Järjestelmä siirtyy lepotilaan 15 sekunnin ajaksi, annosteltavan lääkkeen määrä pysähtyy ja järjestelmä voi jatkaa annoksen antamista uudelleen palattuaan valmiustilaan 15 sekunnin jälkeen.
								</span>
							</p>
							<p class="statusEou">
								Kun 80 annosta on annettu tai on kulunut 24 tuntia järjestelmän aktivoinnista, järjestelmä siirtyy käytön lopettamisen tilaan. Järjestelmä ei enää anna annoksia, LCD-näytöllä vilkkuu annettujen annosten kokonaismäärä, eikä LED-valo enää vilku.
								<span class="mockButton mbEOL">
									Kun järjestelmä on ollut käytön lopettamisen tilassa 12 tuntia, se siirtyy automaattisesti järjestelmän käytön päättymisen tilaan.
								</span>
								<span>
									Annospainikkeen pitäminen pohjassa 6 sekunnin ajan sammuttaa laitteen virran.
								</span>
							</p>
							<p class="statusEol">
								Laite voi HÄLYTTÄÄ, jos ihossa havaitaan ongelmia kesken annostelun, jos akun varaus on vähäinen tai jos laite on ollut käytön lopettamisen tilassa 12 tuntia. Senhetkisen annoksen suuruus vilkkuu LCD-näytöllä, LED-valo vilkkuu tauotta punaisena ja laite antaa jatkuvaa piippausääntä. Tämä osoittaa, että järjestelmää ei enää voida käyttää. Annoksia ei enää anneta.
								<span>
									Annospainikkeen pitäminen pohjassa 6 sekunnin ajan sammuttaa laitteen virran.
								</span>
							</p>
							<p class="statusPoweron"></p>
							<p class="statusPoweroff"></p>
							<p class="statusPoweredoff"></p>
							<p class="statusCustom">custom</p>
						</div>
					</article>
				</div>
			</div>
			<div class="contextArrowContainer">
				<div class="flaticon-arrow395 contextArrow contextArrowClosed"></div>
			</div>
		</div>
		<div class="control">
			<label for="doseNumber"  class="extraButtons hidden" >Set Dose #: </label>
			<input type="number" name="doseNumber" id="doseNumber"  class="extraButtons hidden" min="0" max="99" value="0" ></input>
		</div>
	</div>
</section>
<header class="ionsysLogoBanner hiddenLogo">
	<div class="mdcoLogo">
	</div>
</header>
<section class="infoPage">
	<div class="infoPageContent">
		<table class="infoPageTable">
			<td colspan="2">
				IONSYS on tarkoitettu leikkauksen jälkeisen äkillisen, kohtalaisen tai vakavan kivun hallintaan aikuisilla potilailla.
			</td>
		</table>
		<table class="infoPageTable">
			<td colspan="2">
				IONSYS on tarkoitettu vain sairaalakäyttöön. Hoidon saa aloittaa ja sen tulee pysyä sellaisen lääkärin valvonnassa, jolla on kokemusta opioidihoidon suorittamisesta.
			</td>
		</table>
		<table class="infoPageTable">
			<tr>
				<th colspan="2">
					<h3>JÄRJESTELMÄTIEDOT</h3>
				</th>
			</tr>
			<tr>
				<td>
					Vaikuttava aine 
				</td>
				<td>
					Fentanyyli HCl 
				</td>
			</tr>
			<tr>
				<td>
					Antoreitti: 
				</td>
				<td>
					Transdermaalinen (iontoforeesi) 
				</td>
			</tr>
			<tr>
				<td>
					Aktivointi: 
				</td>
				<td>
					Potilas kaksoisnapsauttaa tarvittaessa annostelupainiketta (kahdesti 3 sekunnin aikana) 
				</td>
			</tr>
			<tr>
				<td>
					Annostelu:
				</td>
				<td>
					Valmiiksi ohjelmoitu 40 mikrogrammaa annostellaan 10 minuutin annosteluvaiheen* aikana 
				</td>
			</tr>
			<tr>
				<td>
					Suurin mahdollinen annostiheys:
				</td>
				<td>
					6 annosta tunnissa 
				</td>
			</tr>
			<tr>
				<td>
					Lukittumisvaihe*:
				</td>
				<td>
					<p>10 minuuttia (samaan aikaan annosteluvaiheen kanssa)</p>
				</td>
			</tr>
			<tr>
				<td>
					Laitekohtainen annosmäärä: 
				</td>
				<td>
					80
				</td>
			</tr>
			<tr>
				<td>
					Annosteluaika: 
				</td>
				<td>
					24 tuntia tai 80 annosta, kumpi vain saavutetaan ensin 
				</td>
			</tr>
			<tr>
				<td colspan="2">
					<p class="infoSidenote">
						*(10 minuutin jakso lyhenee 18 sekuntiin tässä sovelluksessa havainnollistamisen vuoksi)
					</p>
				</td>
			</tr>
		</table>
				<table class="infoPageTable infoColumn" align="left">
					<tbody>
						<th>
							<h3>OMINAISUUDET</h3>
						</th>
						<tr>
							<td>
								<ul>
									<li>Tarvittaessa painettava annospainike</li>
									<li>Hohtodiodi (LED), joka osoittaa: 
										<ul>
											<li>milloin annosta ollaan antamassa (vihreä)</li>
											<li>milloin on tapahtunut virhe (punainen)</li>
										</ul>
									</li>
								</ul>
							</td>
						</tr>
					</tbody>
				</table>
				<table class="infoPageTable infoColumn" align="left">
					<tbody>
						<tr>
							<td>
								<ul>
									<li>Nestekidenäyttö (LCD), joka osoittaa:  </li>
										<ul>
											<li>annettujen annosten lukumäärän</li>
											<li>milloin annosta ollaan antamassa</li>
											<li>milloin on tapahtunut virhe</li>
										</ul>
									<li>Äänimerkit, jotka osoittavat aktivoinnin, ja erilaiset järjestelmähälytykset</li>
									<li>Paineeseen reagoiva kiinnitys, joka pitää IONSYS-laitteen napakasti kiinni potilaan ihossa</li>
								</ul>
							</td>
						</tr>
					</tbody>
				</table>
				<table class="infoPageTable smpc">
					<tr>
						<td>
							<h3>
								IONSYS 40 MICROGRAMS PER DOSE TRANSDERMAL SYSTEM (FENTANYL)
							</h3>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								ABBREVIATED PRESCRIBING INFORMATION 
							</h3>
							<h4>
								(refer to full Summary of Product Characteristics [SmPC] before prescribing).
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Presentations
							</h3>
							<h4>
								IONSYS is a transdermal system. Each IONSYS system contains fentanyl hydrochloride equivalent to 9.7 mg of fentanyl and delivers 40 micrograms fentanyl per dose, to a maximum of 80 doses (3.2 mg/24 hours).

							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Indication
							</h3>
							<h4>
								IONSYS is indicated for the management of acute moderate to severe post-operative pain in adult patients.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Posology and method of administration
							</h3>
							<h4>
								Refer to full SmPC for complete information on posology and administration. IONSYS is a patient-controlled device restricted to hospital use only. Treatment should be initiated by and remain under the guidance of a physician experienced in the management of opioid therapy. Due to the well-known potential of abuse of fentanyl, physicians should evaluate patients for a history of drug abuse.
							</h4>
							<h4>
								<i>Recommended dosage:</i> Each dose delivers 40 micrograms of fentanyl over a 10 minute period. Each unit operates for 24 hours or for 80 doses, whichever comes first, and then becomes inoperative. The maximum treatment duration is 72 hours.
							</h4>
								<i>Elderly (≥65 years): </i>No specific dose adjustment is required. Elderly patients should be observed closely for adverse effects of fentanyl.
							</h4>
							<h4>
								<i>Hepatic or renal impairment:</i> Administer with caution to patients with moderate or severe hepatic or renal impairment
							</h4>
							<h4>
								<i>Paediatric population:</i> Not recommended.
							</h4>
							<h4>
								<i>Method of administration:</i> For transdermal use only. Refer to full SmPC for complete information on method of administration and instructions for use and disposal of IONSYS.  
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Contraindications
							</h3>
							<h4>
								Hypersensitivity to active substance or any excipient.
							</h4>
							<h4>
								Severe respiratory depression or cystic fibrosis.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Special warnings and precautions for use
							</h3>
							<h4>
								IONSYS should be removed before MRI procedure, cardioversion, defibrillation, X-ray, CT scan or diathermy.
							</h4>
							<h4>
								Excessive sweating may reduce delivery of fentanyl.
							</h4>
							<h4>
								<i>Respiratory depression:</i> Significant respiratory depression may occur; patients must be observed for these effects. The use of concomitant CNS-active medicinal products may increase the risk of respiratory depression.
							</h4>
							<h4>
								<i>Chronic pulmonary disease:</i> Patients with chronic obstructive pulmonary disease or patients with conditions pre-disposing them to hypoventilation, may experience more severe adverse reactions. In such patients, opioids may decrease respiratory drive and increase airway resistance.
							</h4>
							<h4>
								<i>Head injuries and increased intracranial pressure:</i> Fentanyl should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention. Fentanyl should be used with caution in patients with brain tumours or other significant space occupying lesions of the brain.
							</h4>
							<h4>
								<i>Cardiac disease:</i> Fentanyl may produce bradycardia or hypotension and should be administered with caution to patients with bradyarrhythmias or any significant cardiovascular disease.
							</h4>
							<h4>
								<i>Paralytic ileus:</i> Should be used with caution in patients with paralytic ileus.
							</h4>
							<h4>
								<i>Abuse potential and dependence:</i> Fentanyl has a well-known abuse potential. Physicians should evaluate patients for a history of drug abuse and follow such patients closely. 
							</h4>
							<h4>
								<i>Hepatic or renal disease:</i> Patients with hepatic or renal impairment should be observed carefully for signs of fentanyl toxicity.
							</h4>
							<h4>
								<i>Elderly patients:</i> Elderly patients should be observed carefully for adverse effects of fentanyl during IONSYS administration.
							</h4>
							<h4>
								<i>Obese patients:</i> Overall adverse reaction profile for morbidly obese patients (BMI > 40) does not suggest a meaningful difference in safety compared to patients with BMI ≤ 40. Caution is advised when prescribing IONSYS in these patients as they may be at increased risk of other respiratory conditions (i.e., sleep apnoea) potentially pre-disposing them to hypoventilation or more severe adverse reactions.
							</h4>
							<h4>
								<i>Hearing impairment:</i> IONSYS should be used with caution in patients with hearing impairment who might not be able to hear the audible signals from the system. 
							</h4>
							<h4>
								<i>Thoracic/chest and upper abdominal surgeries:</i> IONSYS should be used with caution in these patients. 
							</h4>
							<h4>
								<i>Physical status:</i> Safety of IONSYS has not been established in patients with American Society of Anesthesiologists (ASA) physical status classification IV (i.e. patients with a severe systemic disease that is a constant threat to life).
							</h4>
							<h4>
								<i>Patients with genetic polymorphisms affecting CYP3A4 and CYP3A5:</i> IONSYS should be used with caution in these patients. Published literature indicates potential for increased fentanyl exposure in patients with genetic polymorphisms affecting CYP3A4 and CYP3A5; 
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Interaction with other medicinal products and other forms of interaction
							</h3>
							<h4>
								<i>Other CNS depressants:</i> Concomitant use with other CNS depressants may produce additive depressant effects. Hypoventilation, hypotension and profound sedation or coma may occur. Use of other CNS depressants concomitantly with IONSYS requires special patient care and observation.
							</h4>
							<h4>
								<i>CYP3A4 inhibitors: </i>Concomitant use of potent CYP3A4 inhibitors  or moderate CYP3A4 inhibitors  with IONSYS may result in an increase in fentanyl plasma concentrations, which could increase or prolong both the therapeutic effect and adverse reactions, and may cause serious respiratory depression. Concomitant use of potent or moderate CYP3A4 inhibitors and IONSYS is not recommended unless the patient is closely monitored.
							</h4>
							<h4>
								<i>Opioid agonists/antagonists:</i> Concomitant use of partial opioid agonists/antagonists is not recommended as they may induce withdrawal symptoms in opioid dependant patients.
							</h4>
							<h4>
								<i>Serotoninergic medicinal products:</i> Co-administration of fentanyl with a serotoninergic agent may increase the risk of serotonin syndrome. IONSYS is not recommended for use in patients who have received MAOIs within 14 days because severe and unpredictable potentiation by MAOIs has been reported. 
							</h4>
							<h4>
								<i>Topical medicines: </i>Application of IONSYS on skin on which any topical medicine has been applied should be avoided.  
							</h4>
							<h4>
								Refer to full SmPC for further information on interactions. 
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Fertility, pregnancy and lactation
							</h3>
							<h4>
								<i>Pregnancy:</i> No adequate data are available for use of fentanyl in pregnant women. IONSYS should not be used in pregnancy unless clearly necessary. If IONSYS is administered to the mother during this time, an antidote for the child should be readily available.  Following long-term treatment fentanyl may cause withdrawal symptoms in the newborn.
							</h4>
							<h4>
								<i>Breast-feeding:</i> Not recommended for 24 hours following removal of IONSYS. 
							</h4>
							<h4>
								<i>Fertility:</i> There are no clinical data on the effects of fentanyl on fertility. 
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Effects on ability to drive and use machines
							</h3>
							<h4>
								Patients should be advised not to drive or operate machinery if they experience somnolence, dizziness, or visual disturbance.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Undesirable effects 
							</h3>
							<h4>
								The  most commonly reported adverse reactions were nausea, vomiting, and application site reactions. The most serious adverse reactions reported were hypotension and apnoea; all patients should be closely monitored for these. Refer to full SmPC for complete information on other side effects.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Overdose
							</h3>
							<h4>
								Fentanyl overdose effects manifest as an extension of its pharmacologic actions, the most serious effect being respiratory depression. For management of respiratory depression, immediate countermeasures include removing the IONSYS system and physically or verbally stimulating the patient. These actions can be followed by administration of a specific opioid antagonist such as naloxone. Respiratory depression following an overdose may outlast the duration of action of the opioid antagonist therefore repeated administration of the antagonist may be necessary. Reversal of the narcotic effect may also result in acute onset of pain and release of catecholamines. If the clinical situation warrants, a patent airway should be established and maintained, possibly with an oropharyngeal airway or endotracheal tube. Oxygen should be administered and respiration assisted or controlled. If severe or persistent hypotension occurs, hypovolaemia should be considered and the condition should be managed with appropriate parenteral fluid therapy or other interventions. 
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Legal Category
							</h3>
							<h4>
								Prescription only
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Package Quantities & Costs 
							</h3>
							<h4>
								600 GBP for one box containing 6 IONSYS units
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Marketing Authorisation Holder
							</h3>
							<h4>
								line Therapeutics Europe Ltd, 21 St. Thomas Street, Bristol BS1 6JS, United Kingdom.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Marketing Authorisation Number
							</h3>
							<h4>
								EU/1/15/1050/001
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Date of last revision of the API text
							</h3>
							<h4>
								November 2015
							</h4>
							<h4>
								Any suspected adverse reactions should be reported to the local regulatory authority [contact details to be customised per country in line with Appendix V].   
							</h4>
							<h4>
								Adverse events should also be reported to The Medicines Company [add company details tel, email and/or address]
							</h4>
						</td>
					</tr>
				</table>
			</tr>
			</tbody>
	</div>
</section>
<footer class="ionsysLogoBanner logoBannerBottom">
	<div class="ionsysLogo">
	</div>
</footer>
<div class="controlBar">
	<div class="controlButtonsContainer">
		<button id="poorSkin" class="extraButtons" disabled>PSC</button>
		<button id="EOU" class="extraButtons" disabled>
			<span>80/24</span>
		</button>		
		<button id="EOL" class="extraButtons" disabled></button>
		<button id="infoToggle" class="extraButtons">
		</button>	
	</div>
</div>
<audio id="beeper" preload="auto" src="beep.mp3"></audio>
<audio id="beeper-long" preload="auto" src="beep_long.mp3">	</audio>
<audio id="button-press" preload="auto" src="buttonpress.mp3"></audio>

</body>
<script src="http://ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>
<!-- make this a conditional if they are using phonegap and the online / cached copy is not available: -->
<script>window.jQuery || document.write('<script src="jquery-1.10.2.min.js">\x3C/script>')</script>
<script src="jquery-1.11.4-ui.min.js" type="text/javascript"></script>
<script src="jquery.ui.touch-punch.min.js" type="text/javascript"></script>
<script src="jquery.tap.js" type="text/javascript"></script>
<script src="phonegap.js"></script>
<script type="text/javascript" src="script.js"></script>
</html>